A Phase I, Open Label Study Investigating the Disposition of 25 mg/m2 [14C]-AVE8062 (1.85 MBq, 50 microCi) Administered at Cycle 1 as a 30-minute Intravenous Infusion to Patients With Advanced Solid Tumors.

Trial Profile

A Phase I, Open Label Study Investigating the Disposition of 25 mg/m2 [14C]-AVE8062 (1.85 MBq, 50 microCi) Administered at Cycle 1 as a 30-minute Intravenous Infusion to Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2011

At a glance

  • Drugs Ombrabulin (Primary) ; Cisplatin
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Nov 2011 Actual patient number is 3 as reported by ClinicalTrials.gov record.
    • 21 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top